Current Report Filing (8-k)
November 13 2018 - 4:13PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
November 13, 2018
OncoCyte
Corporation
(Exact
name of registrant as specified in its charter)
California
|
|
1-37648
|
|
27-1041563
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
1010
Atlantic Avenue
Suite
102
Alameda,
California 94501
(Address
of principal executive offices)
(510)
775-0515
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “may,”
“will,” “believes,” “plans,” “intends,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual
results to differ materially from the results anticipated in these forward-looking statements are contained in OncoCyte Corporation’s
most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk
Factors” and in other filings that OncoCyte may make with the SEC. Undue reliance should not be placed on these forward-looking
statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.
Except as required by law, OncoCyte disclaims any intent or obligation to update these forward-looking statements.
References
to “OncoCyte,” “we” or “us” are references to OncoCyte Corporation
This
Report and the accompanying Exhibit 99.1 shall be deemed “furnished” and not “filed” under Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of
that section, and shall not be incorporated by reference into any filings made by OncoCyte under the Securities Act of 1933, as
amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing.
Section
2 - Financial Information
Item
2.02 - Results of Operations and Financial Condition
On
November 13, 2018, OncoCyte issued a press release announcing its financial results for the three months ended September 30, 2018.
A copy of the press release is attached as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.
Section
9 - Financial Statements and Exhibits
Item
9.01 - Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ONCOCYTE
CORPORATION
|
|
|
|
Date:
November 13, 2018
|
By:
|
/s/
William Annett
|
|
|
William
Annett
|
|
|
President
and Chief Executive Officer
|
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Apr 2023 to Apr 2024